Pharmacoeconomic effect of compliance with pharmacist’s intervention based on cancer chemotherapy regimens: a cohort study by unknown
Hayashi et al. Journal of Pharmaceutical Health Care and Sciences  (2015) 1:10 
DOI 10.1186/s40780-014-0007-yRESEARCH ARTICLE Open AccessPharmacoeconomic effect of compliance with
pharmacist’s intervention based on cancer
chemotherapy regimens: a cohort study
Makoto Hayashi1,2*†, Akimasa Yamatani1†, Hiromu Funaki1† and Kenichi Miyamoto2†Abstract
Background: It is important for pharmacists to manage cancer chemotherapy regimens in order to achieve safe
treatment. We examined whether there was a useful pharmacoeconomic benefit of compliance the exclusion
criteria of neutropenia, and the importance of a pharmacist's intervention was considered.
Methods: A prospective observational cohort study was conducted at a community-based medical center. Among
374 patients who received chemotherapy between April 2010 and March 2011, 108 patients developed neutropenia
and pharmacists recommended suspension of chemotherapy. These patients were divided into a group in whom
chemotherapy was suspended (complying group) and a group in whom it was continued (non-complying group).
Then the relative dose intensity (RDI) was compared between the two groups, and medical expenses related to
the treatment of neutropenia (neutropenia-related costs: NRC) were compared. Analysis was carried out from the
perspective of the health insurance provider, so only the direct medical costs were evaluated.
Results: There was a significant difference of the RDI between a complying group (85.2 ± 10.0%) and a non-complying
group (79.3 ± 15.0%) (P = 0.021). The average NRC per patient showed a significant difference between the two groups
(complying group: 1,944 ± 412 dollars, non-complying group: 4,394 ± 837 dollars, P = 0.044). The economic effect over
one year was 54,205 dollars.
Conclusion: The present findings suggest that ensuring compliance with chemotherapy regimens (including the
criteria for neutropenia) is effective from a pharmacoeconomic perspective. Accordingly, pharmacists should intervene
as required to improve regimen compliance.
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In 1998, the concept of the regimen was proposed by
the American Society of Health System Pharmacists
(ASHP), American Medical Association (AMA), and the
American Nurses Association (ANA), in order to prevent
medication errors during anticancer chemotherapy [1].
Guidelines for describing all aspects of chemotherapy reg-
imens, including the treatment protocols, order forms,
and product labels, have been proposed by the ASHP and
others. These standards for chemotherapy regimens are* Correspondence: hayashim@kinbyou.hosp.go.jp
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unless otherwise stated.broadly applicable and can be adopted by a wide range of
institutions. Clear and unambiguous medication orders
and consistent descriptions of treatment are important.
Treatment plans and orders should contain enough
information to allow health care providers from diverse
disciplines to compare them with published treatment
regimens and investigational protocols, and must there-
fore include planned dosages and schedules expressed
in patient-specific units. It is important for pharmacists
to be involved in the management of anticancer regimens
so that chemotherapy is performed safely, and there have
been several reports that regimen management by phar-
macists reduces medication errors [2-6].
Dose escalation and shortening of the interval between
courses are two approaches to dose intensification thatl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Coldman hypothesis predicts that delivering higher doses
of anticancer agents will reduce the survival of resistant
clones [11,12], while the Norton-Simon hypothesis goes
beyond previous theories by incorporating the concept of
chemotherapy schedule [12]. These hypotheses both high-
light the role of dose and schedule, and have significantly
influenced oncology practice. Relative dose intensity (RDI)
is an index of the intensity of a particular chemotherapy
regimen [13], and is thought to be an appropriate index
of the curative effect of anticancer treatment. Patients
receiving chemotherapy often experience delay of admin-
istration and dose reduction, leading to a decrease of the
RDI. Dosage are often adjusted because of neutropenia/
febrile neutropenia, since neutropenia is one of the major
side effects of chemotherapy and is an exclusion criterion
in many regimens. When a patient develops neutropenia,
in addition to decreasing the RDI by prolonging the
interval between courses, administration of granulocyte
colony-stimulating factor (G-CSF) may be needed [14].
Under these circumstances, patients often not only receive
inadequate treatment, but medical costs are increased.
Thus, it is desirable to avoid neutropenia and to reduce
medical costs by the pharmacist intervention in regimen
management. However, no reports about the pharmacoeco-
nomic benefits of pharmacist intervention in the manage-
ment of anticancer chemotherapy have been published.
Accordingly, we attempted to show that compliance with
pharmacist intervention based on the cancer chemotherapy
regimen is important and has a pharmacoeconomic effect.
Methods
Regimen checking by pharmacists
The procedure for regimen checking by pharmacists is
shown in Figure 1. First, the attending doctor selectedFigure 1 Chemotherapy flow and regimen checking by pharmacists. Th
into the complying group and the non-complying group depending on whechemotherapy for a patient. Before chemotherapy was
started, a pharmacist reviewed the regimen (administration
schedule and drug dosages) and asked the doctor to alter it
if any problems were detected (Check 1). Before the start
of chemotherapy, if a request for testing the neutrophil
count was not provided by the doctor, a pharmacist
ordered the test instead. If the neutrophil count met
the exclusion criteria, the pharmacist issued a warning.
If the doctor decided to perform chemotherapy anyway,
the pharmacist issued another warning (Check 2).
The exclusion criteria for each regimen were set by our
hospital’s regimen screening committee, which included a
chemotherapy specialist. The criteria for the neutrophil
count were based on the product information for each
medication and on data from clinical trials [15,16].Study design
A prospective observational cohort study was conducted
at a community-based medical center. We enrolled 374
patients who received chemotherapy between April 2010
and March 2011 at the National Hospital Organization
Kanazawa Medical Center in Japan. After starting chemo-
therapy, 108 patients developed neutropenia, and pharma-
cists recommended suspension of chemotherapy based on
the regimen criteria (Table 1).
These 108 patients were divided into a complying
group (n = 58) for whom chemotherapy was suspended,
a non-complying group (n = 38) who continued chemo-
therapy, and another group (n = 12) who received G-CSF
prophylaxis, stopped chemotherapy for reasons other than
neutropenia, or failed to attend hospital regularly.
We performed a retrospective investigation of factors
related to cost effectiveness by performing comparisons
between the complying and non-complying groups.e pharmacist performed the regimen check and patients were classified
ther the doctor followed the pharmacist’s advice.
Table 1 Neutrophil count for suspending treatment with
each anticancer agent
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Costs were investigated by calculating the neutropenia-
related direct medical costs (NRC). These costs were
computed from hospital statements and included drug
costs (G-CSF, etc.) plus all expenses for medical examin-
ation and management.Table 2 Characteristics of the complying and non-complying
Total n = 96 Complying
Age (years) 68.6 ± 10.8 68.2 ± 10.2
Male/female 44/52 27/31
History of chemotherapy (yes/no) 25/71 17/41
ECOG PS (0-1/2) 93/3 57/1
Adjuvant chemotherapy (yes/no) 7/92 6/52
Clinical department (number, %)
Surgery 25 (26.0) 18 (31.0)
Hematology 31 (32.3) 6 (10.3)
Respiratory medicine 19 (19.8) 19 (32.8)
Gastroenterology 11 (11.5) 7 (12.1)
Gynecology 4 (4.2) 4 (6.9)
Urology 5 (5.2) 4 (6.9)
Dental surgery 1 (1.0) 0 (0.0)
Neutrophil count (/mL) 730±245 746±286
Data are expressed as the mean SD or number (%).1)unpaired t-test, 2)Fisher’s exact
performance status. G-CSF, Granulocyte colony-stimulating factor.The relative dose intensity (RDI) was employed as an
index of effective delivery of chemotherapy. RDI was
calculated as the ratio of actual total dose intensity
(ATDI) to the planned total dose intensity (PTDI), and
was expressed as a percentage:
RDI %ð Þ ¼ ATDI=PTDI 100:
PTDI was defined as the average planned dose intensity
over the entire treatment period across all of the chemo-
therapy agents administered. ATDI was calculated by
setting the scheduled regimen dose as 100%.
NRC and RDI were compared between the complying
and non-complying groups. Analysis was carried out from
the perspective of the health insurance provider, so only
medical costs were evaluated.
Statistical analysis
Results are expressed as the mean ± SD or as numbers
(%). For comparison of patient characteristics, age was
compared by the unpaired t-test, while sex, prior chemo-
therapy, Eastern Cooperative Oncology Group perform-
ance status, adjuvant chemotherapy, and clinical
department were evaluated by Fisher’s exact test.
The neutrophil count, RDI, duration of G-CSF therapy,
and NRC were compared by the unpaired t-test, while the
rate of G-CSF use was evaluated by Fisher’s exact test.
Multiple regression analysis was performed to determine
the relationship between NRC and each of the above vari-
ables. Correlations between NRC and each variable were
investigated by univariate analysis, and variables showing
P < 0.05 were included in multiple regression analysis.
To determine the factors influencing the NRC, stepwisegroups
group n = 58 Non-complying group n = 38 P value













test, 3)Mann–Whitney test. ECOG PS, Eastern Cooperative Oncology Group




group n = 58
Non-complying
group n = 38
5-flourouracil 1 1 0
ABVD 2 0 2
AC 7 6 1
Bendamustine 3 0 3
B-mab+CBDCA+PAC 1 1 0
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ent variables: regimen compliance, neutrophil count,
and leukemia. A two-sided statistical test was used in
all analyses and P <0.05 was considered to indicate
significance. Statistical software (Dr SPSS for Windows,
Version 5.0) was employed for these analyses.
This study was approved by the research ethics com-
mittee of Kanazawa Medical Center (No. 2012–002) and
was performed according to the Declaration of Helsinki.B-mab+mFOLFOX6 3 2 1
CBDCA+GEM 2 2 0
CBDCA+VP16 2 2 0
CHOP 5 1 4
DeVIC 2 1 1
DOC 2 0 2
DOXIL 2 2 0
GC 1 1 0
GEM 12 12 2
High dose-AraC 2 0 2
Hign dose MTX 2 0 2
Irinotecan 2 2 0
Pemetrexed + CBDCA 3 3 0
Pemetrexed 1 1 0
PAC+GEM 2 2 0
R-CHOP 3 0 3
Rituximab 1 1 0
R-THPCOP 10 4 6
S1+DOC 2 2 0
S1+CDDP 1 1 0
S1+GEM 8 6 2
SOX 4 1 3
THPCOP 2 0 2
VNR + HER 1 0 1
CBDCA+PAC 1 1 0
Weekly PAC 1 1 0
Weekly PAC+ HER 2 1 1
ABVD: doxorubicin+ bleomycin+ vincristine+ dacarbazine, B-mab: bevacizumab,
CBDCA: carboplatin, PAC: paclitaxel mFOLFOX 6: 5-fluorouracil+ levofolinate+
oxaliplatin, DOC: docetaxel, GEM: gemcitabine, VP16: etoposide,
CHOP: cyclophosphamide+ doxorubicin+ vincristine + predonizorne,
DeVIC: carboplatin+etoposide+ifosfamide, GC: emcitabine+ cisplatin,
AraC: cytarabine, MTX: methotrexate, R: rituximab, THPCOP: rituximap+
cyclophosphamide+pirarubicin+vincristine + Predonizorne, S1: Tegafur+
gimeracil+ oteracil, CDDP: cisplatin, SOX: S1+ oxaliplaton, VNR: vinorelbine,
HER: trastuzumab.Results
Patients
A total of 108 patients developed neutropenia correspond-
ing to the criteria for suspension of treatment. Among
them, 12 patients who received G-CSF prophylaxis were
excluded. The remaining 96 patients were divided into a
complying group (n = 58), which suspended chemotherapy
according to the pharmacist's recommendation, and a
non-complying group (n = 38) that continued chemother-
apy against the pharmacist's recommendation. Then costs
related to treating neutropenia were compared between
the complying group and the non-complying group.
Patient characteristics are listed in Table 2. There were no
differences of clinical factors between the two groups. A
classification of the subjects by chemotherapy regimen is
shown in Table 3. There were no significant differences
between the two groups.
Analysis of Cost effectiveness (Table 4)
There was a significant difference of RDI between the
complying group (85.2 ± 10.0%) and the non-complying
group (79.3 ± 15.0%) (P = 0.021), with the RDI being sig-
nificantly higher in the complying group. Use of G-CSF
for neutropenia was similar, since it was employed in
56.3% of the complying group and 60.5% of the non-
complying group (P = 0.08). However, the duration of
G-CSF treatment was significantly shorter in the comply-
ing group (10.7 ± 14.8 days) than in the non-complying
group (20.7 ± 22.3 days, P = 0.049).
The total neutropenia-related cost (NRC) of treatment,
including the costs for outpatient visits and for hospital-
ization, was 279,731 dollars. It was 112,763 dollars in the
complying group and 166,968 dollars in the non-complying
group. The average NRC per patient showed a significant
difference between the two groups (complying group:
1,944 ± 412 dollars, non-complying group: 4,394 ± 837
dollars, P = 0.044). The economic effect over one year
was 54,205 dollars.
Factors influencing the NRC
The results of univariate analysis of nine variables are
displayed in Table 5. Variables that showed a significant
influence in this analysis were regimen compliance, theneutrophil count, and leukemia (P > 0.05). Multivariate
analysis was performed with these three variables identi-
fied by univariate analysis and the results are shown in
Table 6. Only regimen compliance and leukemia had a
significant independent influence on the NRC (adjusted
r2 = 0.69, P <0.001).
Table 4 Analysis of cost effectiveness
Total n = 96 Complying group n = 58 Non-complying group n = 38 P value
Number using G-CSF 56 (58.3%) 33 (56.9%) 23 (60.5%) 0.8572)
Duration of G-CSF (days) 14.8 ± 10.8 10.7 ± 14.8 20.7 ± 22.3 0.0491)
Total cost G-CSF (days) 279,731 112,763 166,968
Cost of outpatient visit (dollar) 26,131 9,306 16,825
Cost of hospitalization (dollar) 253,600 103,457 150,143
NRC (dollar/patient) 2,914 ± 594 1,944 ± 412 4,394 ± 837 0.0441)
RDI (%) 82.9 ± 13.5 85.2 ± 10 79.3 ± 15 0.0211)
Data are expressed as the mean (SD) or number (%).1)unpaired t-test, 2)Fisher’s exact test. ECOG PS, Eastern Cooperative Oncology Group performance status.
NRC, neutropenia-related costs. RDI, relative dose intensity.
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Regimen compliance, including avoidance of neutropenia,
is important for safe performance of chemotherapy. In the
present study, we examined the pharmacoeconomic effect
of compliance with pharmacist intervention based on
cancer chemotherapy regimens. We found that the NRC
was significantly lower in the complying group who
discontinued chemotherapy according to the regimen
compliance. The reason for the higher NRC in the non-
complying group seemed to be administration of G-CSF
for a longer period than in the complying group. The
expenses that we investigated in this study not only
included the cost of G-CSF itself, but also the other
medical costs for treatment of neutropenia.
In Japan, when a fixed level of medical expenses for
high-cost medical care is exceeded, payment by the patient
is reduced. The results of this study suggest that regimen
management by pharmacists not only contribute to redu-
cing payments by the patient but also to reduction of
overall medical costs [2,3].
There have already been some reports that pharmacist
intervention can contribute to reducing medical costs.
Moore et al. [17] reported that intervention by pharma-
cists targeting the medication of high-risk patients couldTable 5 Correlation coefficients between NRC and other
parameters (univariable analysis)
Variable Correlation coefficient (r) P value
Regimen compliance (yes:1) -0.298 0.0261)
Age (years) 0.115 0.2182)
Male (yes:1) -0.003 0.9801)
Adjuvant therapy (yes:1) -0.256 0.0571)
History of chemotherapy (yes:1) 0.155 0.2541)
ECOG PS (0-1/2) -0.012 0.9291)
Neutrophil count (/μL) -0.197 0.0412)
Malignant lymphoma (yes:1) 0.239 0.0761)
Leukemia (yes:1) 0.457 <0.0011)
Spearman’s correlation coefficient 1), Pearson’s correlation coefficient 2)ECOG
PS, Eastern Cooperative Oncology Group performance status.reduce total costs and treatment costs for diseases such
as diabetes, hypertension, dyslipidemia, depression, and
asthma. In addition, Yu et al. [18] reported that educational
intervention by pharmacists showed excellent cost effect-
iveness for Type 2 diabetes mellitus. The present study
provided evidence that pharmacist intervention in antican-
cer chemotherapy can also improve cost effectiveness.
On the other hand, pharmacist intervention should
not adversely influence the curative effect of chemother-
apy. It has been shown that the RDI is an important
indicator of curative effect [4-6]. In this study, the RDI of
the complying group was clearly higher than that of the
non-complying group. An RDI > 85% appears to improve
the long-term outcome of chemotherapy [19], and the RDI
of the complying group was 85.2%. Because a high RDI
seems to prolong overall survival and the time to progres-
sion, the usefulness of regimen compliance is suggested.
Chemotherapy was continued despite the warning from
the pharmacist in 38 patients for the following reasons.
The attending doctor hoped for a curative effect in 21
patients. In another 9 patients, the neutrophil count was
only slightly below the borderline for suspending treat-
ment. In the remaining 8 patients, the reason could not be
determined. Thus, continuation of treatment against the
advice of the pharmacist was based on the judgment of the
attending doctor, and selection bias regarding continuation
of chemotherapy was not identified.
Multivariate analysis revealed that factors influen-
cing the NRC were regimen observance and treatment
for leukemia. Patients with hematologic malignancies,
particularly leukemia and lymphoma, often show delayed
recovery from severe neutropenia due to their underlyingTable 6 Predictors of the NRC by multiple regression
analysis
Variable β T-value P value VIF
Regimen compliance (yes:1) -0.237 -2.915 0.005 1.025
Neutrophil count (/μL) -0.059 -0.685 0.384 1.152
Leukemia (yes:1) 0.761 8.917 <0.001 1.129
The adjusted coefficient of determination (R2) was 0.66.
β: standardized partial regression coefficient, VIF: variance inflation factor.
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leukemia patients may achieve CR even if treatment is
started when the neutrophil count is decreased. In this
study, there were much more patients with hematologic
malignancies in the non-complying group than in the
complying group, which could be a reason why G-CSF
was administered for longer in the non-complying
group. However, even after adjusting for leukemia and
lymphoma, regimen observance still had an independent
influence on the NRC.
There were some limitations of this study. The first
limitation was that the attending doctor revised the anti-
cancer drug dosages after next courses. In addition, the
timing of resuming chemotherapy may have differed
between inpatients and outpatients. Although inpatients
can undergo daily blood tests, outpatients usually undergo
testing on a weekly basis. However, the number of outpa-
tients was similar in the complying group (n = 12, 20.7%)
and the non-complying group (n = 10, 26.3%), possibly
reflecting the routine use of G-CSF.
The second limitation is that the G-CSF treatment
period depended on the neutrophil count, which was
not necessarily checked every day, so the possibility of a
change in NRC based on the frequency of testing cannot
be denied.
The third limitation of this study is that the RDI was
used as the index of the effect of chemotherapy. A better
index would have been overall survival, which we hope
to employ in a future investigation.
Further, the index of cost was set as NRC in the
present study. Although suspension of chemotherapy is
not only due to neutropenia, this study could not assess
whether other adverse events influenced the suspension
of the chemotherapy.
Despite the above limitations, we conclude that regimen
compliance include neutropenia for chemotherapy has a
beneficial pharmacoeconomic effect and pharmacists have
played the role important for a regimen management.
Although it has already been reported that regimen man-
agement by pharmacists contributes to safety, this is
the first evidence that pharmacist's recommendation to
suspend chemotherapy based on the criteria for neutrophil
counts also has an economic benefit.Conclusions
The present findings suggest that ensuring compliance with
chemotherapy regimens (including the criteria for neutro-
penia) is effective from a pharmacoeconomic perspective.
Accordingly, pharmacists should intervene as required to
improve regimen compliance.Competing interests
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